Samsung BiologicsLtd Management
Management criteria checks 2/4
Samsung BiologicsLtd's CEO is John Chongbo Rim, appointed in Dec 2020, has a tenure of 5.08 years. total yearly compensation is ₩7.90B, comprised of 19% salary and 81% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth ₩467.13M. The average tenure of the management team and the board of directors is 2 years and 2.8 years respectively.
Key information
John Chongbo Rim
Chief executive officer
₩7.9b
Total compensation
| CEO salary percentage | 18.99% |
| CEO tenure | 5.1yrs |
| CEO ownership | 0.0006% |
| Management average tenure | 2yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Still Appears To Be Reasonable
Sep 07
A Look At The Fair Value Of Samsung Biologics Co.,Ltd. (KRX:207940)
Jul 29Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?
Jul 11Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?
Apr 11Samsung Biologics Co.,Ltd.'s (KRX:207940) Popularity With Investors Is Under Threat From Overpricing
Feb 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | ₩2t |
| Sep 30 2025 | n/a | n/a | ₩2t |
| Jun 30 2025 | n/a | n/a | ₩1t |
| Mar 31 2025 | n/a | n/a | ₩1t |
| Dec 31 2024 | ₩8b | ₩2b | ₩1t |
| Sep 30 2024 | n/a | n/a | ₩1t |
| Jun 30 2024 | n/a | n/a | ₩1t |
| Mar 31 2024 | n/a | n/a | ₩895b |
| Dec 31 2023 | ₩7b | ₩1b | ₩858b |
| Sep 30 2023 | n/a | n/a | ₩937b |
| Jun 30 2023 | n/a | n/a | ₩826b |
| Mar 31 2023 | n/a | n/a | ₩793b |
| Dec 31 2022 | ₩5b | ₩1b | ₩798b |
| Sep 30 2022 | n/a | n/a | ₩507b |
| Jun 30 2022 | n/a | n/a | ₩510b |
| Mar 31 2022 | n/a | n/a | ₩480b |
| Dec 31 2021 | ₩3b | ₩598m | ₩394b |
| Sep 30 2021 | n/a | n/a | ₩410b |
| Jun 30 2021 | n/a | n/a | ₩335b |
| Mar 31 2021 | n/a | n/a | ₩265b |
| Dec 31 2020 | ₩995m | ₩421m | ₩241b |
| Sep 30 2020 | n/a | n/a | ₩355b |
| Jun 30 2020 | n/a | n/a | ₩343b |
| Mar 31 2020 | n/a | n/a | ₩278b |
| Dec 31 2019 | ₩1b | ₩497m | ₩203b |
Compensation vs Market: John Chongbo's total compensation ($USD5.46M) is above average for companies of similar size in the KR market ($USD964.30K).
Compensation vs Earnings: John Chongbo's compensation has been consistent with company performance over the past year.
CEO
John Chongbo Rim (64 yo)
Mr. John Chongbo Rim serves as Chairman of Samsung Biologics Co.,Ltd. since March 17, 2023. He has been the CEO & President of Samsung Biologics Co.,Ltd.since December 16, 2020. Mr. Rim has been Director...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman of Board | 5.1yrs | ₩7.90b | 0.00056% ₩ 467.1m | |
| EVP & Head of Co-Prosperity Cooperation Center | no data | ₩2.80b | 0.0065% ₩ 5.4b | |
| Executive VP | no data | ₩2.20b | 0.00013% ₩ 108.4m | |
| EVP, CFO | 1.1yrs | no data | no data | |
| Executive VP & Head of Operation Center | 2yrs | no data | no data | |
| EVP, Head of Sales & Operations Department | 1.1yrs | no data | no data | |
| Executive VP | 2yrs | no data | no data | |
| Executive VP & Head of CDO Development Center | 3yrs | no data | no data | |
| Executive VP | no data | ₩569.00m | no data | |
| VP & Head of Business Consulting Team | no data | no data | no data | |
| VP & Head of Regulatory Affairs | 2.4yrs | no data | no data | |
| VP & Head of DS Department | 2yrs | no data | no data |
Experienced Management: A207940's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman of Board | 5.8yrs | ₩7.90b | 0.00056% ₩ 467.1m | |
| Executive VP | 2.8yrs | ₩2.20b | 0.00013% ₩ 108.4m | |
| EVP, CFO | no data | no data | no data | |
| Independent Outside Director | 5.8yrs | no data | no data | |
| Independent Director | no data | no data | no data | |
| Independent Director | 1.8yrs | no data | no data | |
| Independent Director | less than a year | no data | no data |
Experienced Board: A207940's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/24 21:31 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Samsung Biologics Co.,Ltd. is covered by 45 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nithya Balasubramanian | Bernstein |
| Girish Bakhru | BofA Global Research |
| Hyeryeong Kim | CGS International |